On August 6, 2025, Prothena Corporation announced that its partner, Novo Nordisk, will advance the drug coramitug into Phase 3 development for treating ATTR amyloidosis with cardiomyopathy. This is a significant development for the company.
AI Assistant
PROTHENA CORP PUBLIC LTD CO
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.